PCYN (Procyon) YoY EBITDA Growth: 54.55% (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCYN Procyon Corp PCYN
48 GF Score
Price $0.26
View Full Analysis

What is Procyon YoY EBITDA Growth?

Procyon PCYN 48 YoY EBITDA Growth is 54.55% as of Jun. 2024. GuruFocus rates PCYN with a GF Score™ of 48/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Procyon's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 54.55%.

Procyon's EBITDA per Share for the three months ended in Jun. 2024 was $0.02.

Procyon YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Procyon's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procyon YoY EBITDA Growth Chart

Procyon Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.22 390.91 -102.78 800.00 -42.86

Procyon Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 257.14 -80.00 -233.33 -300.00 54.55
PCYN
48GF Score
Procyon Corp PCYN
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procyon YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Procyon's YoY EBITDA Growth for the fiscal year that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (A: Jun. 2024 )
=(EBITDA per Share (A: Jun. 2024 )-EBITDA per Share (A: Jun. 2023 ))/ | EBITDA per Share (A: Jun. 2023 ) |
=(0.012-0.021)/ | 0.021 |
=-42.86 %

Procyon's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(0.017-0.011)/ | 0.011 |
=54.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 54.55% mean?
Procyon (PCYN) has a YoY EBITDA Growth of 54.55% as of Jun. 2024. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Procyon and its competitors.
Is Procyon's YoY EBITDA Growth too high?
Procyon's current YoY EBITDA Growth is 54.55%. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's YoY EBITDA Growth compare to KAYS and YCBD?
Procyon's YoY EBITDA Growth of 54.55% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Procyon and its competitors. Procyon's current YoY EBITDA Growth is 54.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current YoY EBITDA Growth of 54.55%. The current YoY EBITDA Growth is 54.55%. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Procyon (PCYN), the current YoY EBITDA Growth is 54.55% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Procyon Business Description

Address 164 Douglas Road East, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score

Get the complete analysis for PCYN

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price